{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:05:36Z","timestamp":1790330736475,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40268-016-0123-2","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T06:10:03Z","timestamp":1456985403000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and Safety Profile of Diclofenac\/Cyclodextrin and Progesterone\/Cyclodextrin Formulations: A Review of the Literature Data"],"prefix":"10.1007","volume":"16","author":[{"given":"Cristina","family":"Scavone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Colomba","family":"Bonagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cimmaruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosina","family":"Cenami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Torella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"key":"123_CR1","unstructured":"Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). August 2000 BP. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm070246.pdf . Accessed 14 Jan 2016."},{"key":"123_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005964","volume":"30","author":"S Kumar","year":"2013","unstructured":"Kumar S, Bhargava D, Thakkar A, Arora S. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. Crit Rev Ther Drug Carrier Syst. 2013;30:217\u201356.","journal-title":"Crit Rev Ther Drug Carrier Syst."},{"key":"123_CR3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.colsurfb.2013.09.035","volume":"114","author":"B Gidwani","year":"2014","unstructured":"Gidwani B, Vyas A. Synthesis, characterization and application of epichlorohydrin-\u03b2-cyclodextrin polymer. Colloids Surf B Biointerfaces. 2014;114:130\u20137.","journal-title":"Colloids Surf B Biointerfaces."},{"key":"123_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","volume":"329","author":"T Loftsson","year":"2007","unstructured":"Loftsson T, Duch\u00eane D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329:1\u201311.","journal-title":"Int J Pharm."},{"key":"123_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/0975-7406.67003","volume":"2","author":"G Tiwari","year":"2010","unstructured":"Tiwari G, Tiwari R, Rai AK. Cyclodextrins in delivery systems: applications. J Pharm Bioallied Sci. 2010;2:72\u20139.","journal-title":"J Pharm Bioallied Sci."},{"key":"123_CR6","first-page":"963","volume":"27","author":"G Murtaza","year":"2014","unstructured":"Murtaza G, Khan SA, Najam-ul-Haq M, Hussain I. Comparative evaluation of various solubility enhancement strategies for furosemide. Pak J Pharm Sci. 2014;27:963\u201373.","journal-title":"Pak J Pharm Sci."},{"key":"123_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2174\/15701638113106660043","volume":"11","author":"M Semalty","year":"2014","unstructured":"Semalty M, Panchpuri M, Singh D, Semalty A. Cyclodextrin inclusion complex of racecadotril: effect of drug-\u03b2-cyclodextrin ratio and the method of complexation. Curr Drug Discov Technol. 2014;11:154\u201361.","journal-title":"Curr Drug Discov Technol."},{"issue":"10","key":"123_CR8","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/jps.20992","volume":"96","author":"T Loftsson","year":"2007","unstructured":"Loftsson T, Vogensen SB, Brewster ME, Konr\u00e1dsd\u00f3ttir F. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci. 2007;96(10):2532\u201346.","journal-title":"J Pharm Sci."},{"key":"123_CR9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.arcmed.2014.11.020","volume":"45","author":"M Vecserny\u00e9s","year":"2014","unstructured":"Vecserny\u00e9s M, Fenyvesi F, B\u00e1cskay I, et al. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases. Arch Med Res. 2014;45:711\u201329.","journal-title":"Arch Med Res."},{"key":"123_CR10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.carbpol.2013.08.078","volume":"101","author":"E Pinho","year":"2014","unstructured":"Pinho E, Grootveld M, Soares G, Henriques M. Cyclodextrins as encapsulation agents for plant bioactive compounds. Carbohydr Polym. 2014;101:121\u201335.","journal-title":"Carbohydr Polym."},{"issue":"1","key":"123_CR11","first-page":"5","volume":"2","author":"UM Hanumegowda","year":"2014","unstructured":"Hanumegowda UM, Wu Y, Adams SP. Potential impact of cyclodextrin-containing formulations in toxicity evaluation of novel compounds in early drug discovery. J Pharm Pharmacol. 2014;2(1):5.","journal-title":"J Pharm Pharmacol."},{"issue":"1","key":"123_CR12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CAD.0b013e32833f6d22","volume":"22","author":"TK Stutchbury","year":"2011","unstructured":"Stutchbury TK, Vine KL, Locke JM, Chrisp JS, Bremner JB, Clingan PR, et al. Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Anticancer Drugs. 2011;22(1):24\u201334.","journal-title":"Anticancer Drugs."},{"issue":"8","key":"123_CR13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1211\/0022357001774831","volume":"52","author":"MS Nagarsenker","year":"2000","unstructured":"Nagarsenker MS, Meshram RN, Ramprakash G. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats. J Pharm Pharmacol. 2000;52(8):949\u201356.","journal-title":"J Pharm Pharmacol."},{"key":"123_CR14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0378-5173(91)90161-G","volume":"70","author":"FJ Otero Espinar","year":"1991","unstructured":"Otero Espinar FJ, Anguiano Igea S, Blanco Medez J, Vila Jato JL. Reduction in the ulcerogenicity of naproxen by complexation with \u03b2-cyclodextrin. Int J Pharm. 1991;70:35\u201341.","journal-title":"Int J Pharm."},{"key":"123_CR15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/026520399283984","volume":"16","author":"GA Koutsou","year":"1999","unstructured":"Koutsou GA, Storey DM, B\u00e4r A. Gastrointestinal tolerance of gamma-cyclodextrin in humans. Food Addit Contam. 1999;16:313\u20137.","journal-title":"Food Addit Contam."},{"key":"123_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","volume":"36","author":"VJ Stella","year":"2008","unstructured":"Stella VJ, He Q. Cyclodextrins. Toxicol Pathol. 2008;36:30\u201342.","journal-title":"Toxicol Pathol."},{"key":"123_CR17","volume-title":"Farmacologia per le professioni sanitarie","author":"A Capuano","year":"2014","unstructured":"Capuano A, Parretta E. Farmaci dell\u2019infiammazione. In: Rossi F, Cuomo V, Riccardi C, editors. Farmacologia per le professioni sanitarie. 1st ed. Torino: Edizione Minerva Medica; 2014.","edition":"1"},{"key":"123_CR18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/ph5111160","volume":"5","author":"FG Smith","year":"2012","unstructured":"Smith FG, Wade AW, Lewis ML, Qi W. Cyclooxygenase (COX) inhibitors and the newborn kidney. Pharmaceuticals (Basel). 2012;5:1160\u201376.","journal-title":"Pharmaceuticals (Basel)."},{"key":"123_CR19","unstructured":"Mazzotti A, Chiarello E, Tedesco G, et al. Utilizzo del diclofenac idrossipropil-\u03b2-ciclodestrina nella gestione del dolore post-operatorio in pazienti trattati per chirurgia minore dell\u2019arto inferiore. G Ital Ortop Traumatolog. 2015;41:30\u201335. Available at: http:\/\/www.giot.it\/wp-content\/uploads\/2015\/05\/GIOT_1-2015.pdf . Accessed 14 Jan 2016."},{"key":"123_CR20","unstructured":"Prettyman J. Subcutaneous or intramuscular? Confronting a parenteral administration dilemma. Medsurg Nurs. 2005;14(2):93\u20138 (quiz 99)."},{"key":"123_CR21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cld.2013.07.009","volume":"17","author":"A Unzueta","year":"2013","unstructured":"Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis. 2013;17:643\u201356.","journal-title":"Clin Liver Dis."},{"key":"123_CR22","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.2174\/09298673113209990115","volume":"20","author":"C Scarpignato","year":"2013","unstructured":"Scarpignato C. Piroxicam-\u03b2-cyclodextrin: a GI safer piroxicam. Curr Med Chem. 2013;20:2415\u201337.","journal-title":"Curr Med Chem."},{"key":"123_CR23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clinthera.2013.03.014","volume":"35","author":"DB Carr","year":"2013","unstructured":"Carr DB, McDonnell Moorehead T, Bouchard A, et al. Effects of injectable HP\u03b2CD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo. Clin Ther. 2013;35:646\u201358.","journal-title":"Clin Ther."},{"key":"123_CR24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1185\/03007995.2011.649848","volume":"28","author":"K Pavelka","year":"2012","unstructured":"Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomized controlled trial. Curr Med Res Opin. 2012;28:172\u20138.","journal-title":"Curr Med Res Opin."},{"key":"123_CR25","unstructured":"The Medicines Utilization Monitoring Centre. National report on medicine use in Italy 2013. Rome: Italian Medicines Agency; 2014. Available at: http:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/Rapporto_OsMED_2013.pdf . Accessed 14 Jan 2016."},{"key":"123_CR26","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1185\/03007995.2010.486301","volume":"26","author":"TJ Gan","year":"2010","unstructured":"Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26:1715\u201331.","journal-title":"Curr Med Res Opin."},{"key":"123_CR27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1517\/14740338.7.2.167","volume":"7","author":"F Iraji","year":"2008","unstructured":"Iraji F, Siadat AH, Asilian A, et al. The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf. 2008;7:167\u201372.","journal-title":"Expert Opin Drug Saf."},{"key":"123_CR28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/BF03261999","volume":"35","author":"J Castellsague","year":"2012","unstructured":"Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35:1127\u201346.","journal-title":"Drug Saf."},{"issue":"Suppl 1","key":"123_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199300451-00008","volume":"45","author":"P Gagnier","year":"1993","unstructured":"Gagnier P. Review of the safety of diclofenac\/misoprostol. Drugs. 1993;45(Suppl 1):31\u20135.","journal-title":"Drugs."},{"key":"123_CR30","unstructured":"Assessment report for non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. Review under article 5(3) of Regulation (EC) No 726\/2004. Procedure no: EMEA\/H\/A-5(3)\/1319. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2012\/11\/WC500134717.pdf . Accessed 14 Jan 2016."},{"key":"123_CR31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-5173(03)00366-1","volume":"263","author":"MM Dias","year":"2003","unstructured":"Dias MM, Raghavan SL, Pellett MA, Hadgraft J. The effect of beta-cyclodextrins on the permeation of diclofenac from supersaturated solutions. Int J Pharm. 2003;263:173\u201381.","journal-title":"Int J Pharm."},{"key":"123_CR32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.5414\/CP201600","volume":"50","author":"M Zeitlinger","year":"2012","unstructured":"Zeitlinger M, Rusca A, Oraha AZ, et al. Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. Int J Clin Pharmacol Ther. 2012;50:383\u201390.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"123_CR33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CP201963","volume":"52","author":"S Salomone","year":"2014","unstructured":"Salomone S, Piazza C, Vitale DC, et al. Pharmacokinetics of a new subcutaneous diclofenac formulation administered to three body sites: quadriceps, gluteus, and abdomen. Int J Clin Pharmacol Ther. 2014;52:129\u201334.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"123_CR34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/phar.1304","volume":"33","author":"F Mermelstein","year":"2013","unstructured":"Mermelstein F, Hamilton DA, Wright C, et al. Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HP\u03b2CD-diclofenac (Dyloject) compared with other diclofenac formulations. Pharmacotherapy. 2013;33:1012\u201321.","journal-title":"Pharmacotherapy."},{"key":"123_CR35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/papr.12082","volume":"14","author":"T Dietrich","year":"2014","unstructured":"Dietrich T, Leeson R, Gugliotta B, Petersen B. Efficacy and safety of low dose subcutaneous diclofenac in the management of acute pain: a randomized double-blind trial. Pain Pract. 2014;14:315\u201323.","journal-title":"Pain Pract."},{"key":"123_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00115550-200707000-00006","volume":"32","author":"RM Leeson","year":"2007","unstructured":"Leeson RM, Harrison S, Ernst CC, et al. Dyloject, a novel injectable diclofenac formulation, offers greater safety and efficacy than voltarol for postoperative dental pain. Reg Anesth Pain Med. 2007;32:303\u201310.","journal-title":"Reg Anesth Pain Med."},{"key":"123_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/papr.12140","volume":"15","author":"E Chiarello","year":"2015","unstructured":"Chiarello E, Bernasconi S, Gugliotta B, Giannini S. Subcutaneous injection of diclofenac for the treatment of pain following minor orthopedic surgery (DIRECT study): a randomized trial. Pain Pract. 2015;15:31\u20139.","journal-title":"Pain Pract."},{"key":"123_CR38","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1213\/ANE.0b013e3182691bf9","volume":"115","author":"TJ Gan","year":"2012","unstructured":"Gan TJ, Daniels SE, Singla N, et al. A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesth Analg. 2012;115:1212\u201320.","journal-title":"Anesth Analg."},{"key":"123_CR39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2344\/0003-3006-58.2.73","volume":"58","author":"K Christensen","year":"2011","unstructured":"Christensen K, Daniels S, Bandy D, et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesth Prog. 2011;58:73\u201381.","journal-title":"Anesth Prog."},{"key":"123_CR40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/AJP.0b013e318270f957","volume":"29","author":"S Daniels","year":"2013","unstructured":"Daniels S, Melson T, Hamilton DA, et al. Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial. Clin J Pain. 2013;29:655\u201363.","journal-title":"Clin J Pain."},{"key":"123_CR41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/pme.12076","volume":"14","author":"JE Chelly","year":"2013","unstructured":"Chelly JE, Singla SK, Melson TI, et al. Safety of a novel parenteral formulation of diclofenac after major orthopedic or abdominal\/pelvic surgery in a population including anticoagulated, elderly or enally insufficient patients: an open-label, multiday, repeated dose clinical trial. Pain Med. 2013;14:749\u201361.","journal-title":"Pain Med."},{"key":"123_CR42","volume-title":"Farmacologia\u2014principi di base e applicazioni terapeutiche","author":"PL Canonico","year":"2005","unstructured":"Canonico PL, Schettini G. Ormoni e farmaci del sistema endocrino. In: Rossi F, Cuomo V, Riccardi C, editors. Farmacologia\u2014principi di base e applicazioni terapeutiche. 1st ed. Torino: Edizione Minerva Medica; 2005.","edition":"1"},{"key":"123_CR43","doi-asserted-by":"crossref","unstructured":"DeMayo FJ, Zhao B, Takamoto N, Tsai SY. Mechanisms of action of estrogen and progesterone. Ann N Y Acad Sci. 2002;955:48\u201359 (discussion 86\u20138, 396\u2013406).","DOI":"10.1111\/j.1749-6632.2002.tb02765.x"},{"key":"123_CR44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/13625180400007736","volume":"9","author":"G Benagiano","year":"2004","unstructured":"Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care. 2004;9:182\u201393.","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"123_CR45","unstructured":"Prontogest\u00ae (IBSA Farmaceutici Italia). Summary of product characteristics. Available at: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_007166_005239_RCP.pdf&retry=0&sys=m0b1l3 . Accessed 14 Jan 2016."},{"key":"123_CR46","unstructured":"Antela\u00ae (Farmitalia Industria Chimico Farmaceutica). Summary of product characteristics. Available at: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_000959_040389_RCP.pdf&retry=0&sys=m0b1l3 . Accessed 14 Jan 2016."},{"key":"123_CR47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0039-128X(00)00121-5","volume":"65","author":"T Levy","year":"2000","unstructured":"Levy T, Yairi Y, Bar-Hava I, et al. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids. 2000;65:645\u20139.","journal-title":"Steroids."},{"key":"123_CR48","unstructured":"Lentogest\u00ae (IBSA Farmaceutici Italia). Riassunto delle Caratteristiche del Prodotto. Available at: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_007166_024542_RCP.pdf&retry=0&sys=m0b1l3 . Accessed 14 Jan 2016."},{"key":"123_CR49","unstructured":"Berrino F, Campagnoli C, Veronesi U. Progesterone, progestinici e rischio di cancro mammario nella terapia ormonale sostitutiva. Available at: https:\/\/www.progettoasco.it\/riviste\/rivista_simg\/2005\/04_2005\/8.pdf . Accessed 14 Jan 2016."},{"key":"123_CR50","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-14-0252","volume":"54","author":"CH Diep","year":"2015","unstructured":"Diep CH, Daniel AR, Mauro LJ, Knutson TP, Lange CA. Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 2015;54:R31\u201353.","journal-title":"J Mol Endocrinol."},{"key":"123_CR51","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1208\/pt040101","volume":"4","author":"I Nandi","year":"2003","unstructured":"Nandi I, Bateson M, Bari M, Joshi HN. Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone. AAPS PharmSciTech. 2003;4:E1.","journal-title":"AAPS PharmSciTech."},{"key":"123_CR52","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1002\/jps.22033","volume":"99","author":"A Dahan","year":"2010","unstructured":"Dahan A, Miller JM, Hoffman A, et al. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci. 2010;99:2739\u201349.","journal-title":"J Pharm Sci."},{"key":"123_CR53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/03639040600897093","volume":"32","author":"M Lahiani-Skiba","year":"2006","unstructured":"Lahiani-Skiba M, Barbot C, Bounoure F, et al. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems. Drug Dev Ind Pharm. 2006;32:1043\u201358.","journal-title":"Drug Dev Ind Pharm."},{"key":"123_CR54","first-page":"3167","volume":"7","author":"DM Ragab","year":"2012","unstructured":"Ragab DM, Rohani S, Consta S. Controlled release of 5-fluorouracil and progesterone from magnetic nanoaggregates. Int J Nanomedicine. 2012;7:3167\u201389.","journal-title":"Int J Nanomedicine."},{"key":"123_CR55","doi-asserted-by":"crossref","unstructured":"Patil A, Swamy G, Murtha A, Heine RP, Grotegut C. Comparative efficacy of water-soluble progesterone vs traditional progesterone formulation on uterine contractility. Am J Obste Gynecol. 2015;212(1 Suppl):S304. Available at: http:\/\/www.ajog.org\/article\/S0002-9378(14)01873-0\/pdf . Accessed 14 Jan 2016.","DOI":"10.1016\/j.ajog.2014.10.818"},{"key":"123_CR56","unstructured":"Public assessment report: decentralised procedure. Lubion 25\u00a0mg powder for solution for injection; Lubion 25 mg solution for injection. Progesterone. UK\/H\/4170\/001-02\/DC. Available at: http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con270678.pdf . Accessed 14 Jan 2016."},{"key":"123_CR57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/09513590.2012.736560","volume":"29","author":"M Sator","year":"2013","unstructured":"Sator M, Radicioni M, Cometti B, et al. Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route. Gynecol Endocrinol. 2013;29:205\u20138.","journal-title":"Gynecol Endocrinol."},{"key":"123_CR58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2013.09.010","volume":"101","author":"G Lockwood","year":"2014","unstructured":"Lockwood G, Griesinger G. Cometti B; 13 European Centers. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertil Steril. 2014;101:112\u20139.","journal-title":"Fertil Steril."},{"key":"123_CR59","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/humrep\/deu194","volume":"29","author":"VL Baker","year":"2014","unstructured":"Baker VL, Jones CA, Doody K, et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Hum Reprod. 2014;29:2212\u201320.","journal-title":"Hum Reprod."},{"key":"123_CR60","unstructured":"European Medicines Agency. Background review for cyclodextrins used as excipients. EMA\/CHMP333892\/2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2014\/12\/WC500177936.pdf . Accessed 14 Jan 2016."},{"key":"123_CR61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.acpain.2008.11.001","volume":"11","author":"RD Colucci","year":"2009","unstructured":"Colucci RD, Wright C IV, Mermelstein FH, Gawarecki DG, Carr DB. Dyloject\u00ae, a novel injectable diclofenac solubilised with cyclodextrin: reduced incidence of thrombophlebitis compared to injectable diclofenac solubilised with polyethylene glycol and benzyl alcohol. Acute Pain. 2009;11:15\u201321.","journal-title":"Acute Pain."},{"key":"123_CR62","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3797\/scipharm.0808-05","volume":"76","author":"A Rasheed","year":"2008","unstructured":"Rasheed A, Ashok Kumar CK, Sravanthi VV. Cyclodextrins as drug carrier molecule: a review. Sci Pharm. 2008;76:567\u201398.","journal-title":"Sci Pharm."},{"key":"123_CR63","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0032-9592(03)00258-9","volume":"39","author":"EM Martin Del Valle","year":"2004","unstructured":"Martin Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033\u201346.","journal-title":"Process Biochem."},{"key":"123_CR64","first-page":"117","volume":"4","author":"T Higuchi","year":"1965","unstructured":"Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instrum. 1965;4:117\u2013212.","journal-title":"Adv Anal Chem Instrum."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0123-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0123-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0123-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T02:10:47Z","timestamp":1567649447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0123-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["123"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0123-2","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}